Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Carcinoma

Carcinoma, Lobular

Breast Diseases

Skin Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Up to 12 participants at each evaluation timepoint (approximately every 3-6 months to follow standard of care visits) will have up to 40 mL of blood drawn and distributed into 8 cell-free DNA Streck tubes, for plasma isolation, cell free DNA extraction, and ctDNA analysis. Blood for ctDNA analysis will be collected within +/- 14 days of whole body imaging studies which will occur when patients are scheduled for standard of care whole body imaging.

Blood Specimen

Astrid Quirarte

Rita Mukhtar, MD

A. Jo Chien, MD

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

Primary Aims:

1. To evaluate the feasibility of developing a histologic based registry for participants living with metastatic lobular breast cancer.
2. To understand the natural history, treatment patterns, and overall survival in patients with metastatic ILC using modern, real-world data.

Secondary Aims:

1. To evaluate the correlation between imaging findings and disease progression.
2. To evaluate the correlation between ctDNA and disease progression.
3. To develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials.

Outline:

Participants will be recruited to participate in the registry during a regularly scheduled clinic visit with their treating oncologist, and consented to participate at this time. At each evaluation time point, participants will have a blood draw performed. Participants will be followed until loss to follow up, death, or withdrawal from the registry.

Blood samples will be obtained from participants

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer

Feasibility is defined as enrollment of 10-12 patients with metastatic ILC in the first 2 years across all participating sites, and collection of clinical assessments in \>=75% of treating medical oncologists

Proportion of patients with measurable disease versus unmeasurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) will be reported for each line of treatment as determined by their oncologist.

The median Progression-free survival rate (PFS) for participants enrolled in the registry will be utilized to develop the ILC specific response assessment tool.

The overall rate of survival for participants enrolled in the registry will be utilized to develop the ILC specific response assessment tool.

The overall proportion of participants who are currently taking estrogen receptor modulators or degraders which may interfere with a radiolabeled form of estradiol (FES) in a positron Emission Tomography (PET) versus the participants medical oncologist assessment of disease progression will be utilized to develop the ILC specific response assessment tool.

The overall change in quantity of ctDNA mean tumor molecules per mL blood versus medical oncologist assessment of disease progression will be utilized to develop the ILC specific response assessment tool.

The number of novel imaging tools developed during the course of data collection to improve the determination of disease status will be utilized to develop the ILC specific response assessment tool.

The number of participants who have detectable mutations on ctDNA evaluations with are correlated with health outcomes will be utilized to develop the ILC specific response assessment tool.

The number of participants with metastatic ILC who have enrolled on a clinical trial will be utilized to develop the ILC specific response assessment tool.

University of California, San Francisco

Diseases and Abnormalities at or Before Birth

Eye Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Rare Diseases

Congenital Abnormalities

Aniridia

Wilms Tumor

Beckwith-Wiedemann Syndrome

Urogenital Abnormalities

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Syndrome

Neoplastic Syndromes, Hereditary

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genetic Diseases, Inborn

Eye Abnormalities

Eye Diseases, Hereditary

Iris Diseases

Uveal Diseases

Wilms' Tumor

Hemihypertrophy

Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.

Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.

Questionnaire

Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.

Blood specimen

Louise C. Strong, MD

The goal of this clinical research study is to collect information and blood samples to try to learn why some people develop cancers and tumors, why some families have more cancers than others, and whether certain genes or regions of DNA (the genetic material of cells) affect a person's risk of getting cancer.

This is an investigational study.

Up to 1500 patients and family members will take part in this study. All will be enrolled at MD Anderson.

If you choose to take part in this study, blood (about 10 teaspoons) will be drawn for genetic testing. The blood may be drawn more than 1 time, depending on how much blood is drawn at the first visit, and if you are available for more blood draws. If this is the case, your doctor will discuss any extra blood draws with you.

For small children (less than 5 years old), about 2 teaspoons will be drawn. Children who are 5 years old or older will not have more than 3 teaspoons drawn.

You will complete a questionnaire about your medical history and family medical history. The questionnaire should take about 1 hour to complete. The study staff will also review your medical records.

You will be asked to allow the study staff to collect any of your tissue (whether healthy or cancerous) that is leftover from surgeries performed as part of your standard care. This may be from any past or future surgeries or any tissue being stored at MD Anderson or elsewhere. No new surgeries or biopsies will be performed for this study.

Before your information, tissue samples, and/or bodily fluids can be used for research, the people doing the research must get specific approval from the Institutional Review Board (IRB) of MD Anderson. The IRB is a committee made up of doctors, researchers, and members of the community. The IRB is responsible for protecting the participants involved in research studies and making sure all research is done in a safe and ethical manner. All research done at MD Anderson, including research involving your information, tissue samples, and/or bodily fluids, must first be approved by the IRB.

You may be contacted either by phone or mail 1 time a year, so that the study staff can update your medical history and information. If contacted by phone, this call should last about 30 minutes.

Blood sample(s) for genetic testing. Also, tissue samples, and/or bodily fluids (whether healthy or cancerous) left over from surgeries or procedures performed as part of standard care. The purpose of this clinical research study is to find out why some people develop cancers and tumors, why some families have more cancers than others, and whether certain genes or regions of DNA affect a person's risk of getting cancer.

Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies

Characterize genetic events by a combined molecular biology/epidemiologic approach

National Cancer Institute (NCI)

M.D. Anderson Cancer Center

Blood and Lymph Conditions

Heart and Blood Diseases

Myeloproliferative Disorders

Polycythemia Vera

Polycythemia

Thrombocytosis

Thrombocythemia, Essential

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Bone Marrow Diseases

Blood Platelet Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Chronic Myeloproliferative Disorders

Essential Thrombocythemia

subject who has polycythemia vera or essential thrombocythemia

Ronald Hoffman, MD

The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.

Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.

Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC.

CD34+ cells isolated from the peripheral blood Splenic CD34+ cells

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53

Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.

Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.

The Leukemia and Lymphoma Society

Icahn School of Medicine at Mount Sinai

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Patients new to The Lung Health Check (TLHC) pilot who are attending their first lung health check

Patients who have already undergone one lung health check as part of the TLHC programme, and are now being followed up at 3 months (B1), 12 months (B2) or other (BX) due to an indeterminate finding (e.g. lung nodule)

Patients who are already part of TLHC attending for routine 'incident' round follow-up scanning (usually at approximately 24 months)

Participants with interstitial lung abnormalities (ILAs) identified as part of TLHC, who are referred to the interstitial lung disease (ILD) unit at Royal Brompton Hospital.

Richard Lee

Sejal Jain

Anand Deveraj

Dr Anand Deveral

CT screening of lung cancer offers an opportunity to diagnose early stage lung cancers which is associated with better prognosis - indeterminate results delay diagnosis whilst interval imaging is awaited to assess risk of cancer. This study will allow us to examine the potential of blood-based biomarkers to augment CT screening for lung cancer.

Hypotheses

1. Blood and sputum samples can be collected in patients attending lung health checks as part of the Lung Health Check pilot in West London at fixed and mobile scanners and safely transported for processing and storage in preparation for biomarker development.
2. The biomarkers will help to identify cohorts of

   1. High-risk patients in whom CT surveillance should be conducted more readily/frequently and diagnostic procedures performed earlier.
   2. Low-risk patients who might need reduced surveillance intensity.
   3. Patients with interstitial lung abnormalities that share similar biomarker characteristics to patients with clinically significant interstitial lung disease

1. Background 1.1 Lung cancer \& CT screening Over 46,000 cases of lung cancer are diagnosed every year in the UK, making it the 3rd most common cancer type. Lung cancer is the biggest cause of cancer mortality in the UK and worldwide due to late presentation in the majority of cases. One year survival for lung cancer ranges from 83% at stage I to 17% in stage IV disease (CRUK data).

   Reduced lung cancer mortality (20-26%) can be achieved by Lung Health Checks - which use 'low dose' CT (LDCT) scans of high-risk populations (e.g. heavy smokers), by increasing the proportion of cases diagnosed at an earlier stage when the treatment options are better (National Lung Cancer Screening Trial and NELSON studies). A number of pilot trials within the UK have led to a commitment by NHS England to roll-out a £70m national pilot. RM Partners commenced recruitment to one of the earlier pilots across two clinical commissioning groups (CCGs) in West London in 2018, inviting approximately 1000 patients for an LDCT scan at a fixed and mobile scanner (based in a supermarket car park). This pilot will be extended in 2019-2020 with a further 1000-2000 patients - this will include both new patients and others who will have a 24 month 'incident scan' to re-examine for any new cancer after a previously normal baseline scan). This study will test the uptake and feasibility of biomarker testing and potential scientific opportunities from specimens received.

   1.2 Current Limitations of Lung Health Checks A) Patient Selection: Two lung cancer risk calculators, the modified Liverpool Lung Project (LLPv2) and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) are both multivariate risk prediction models which have been used to select patients for screening. Both models have been used to support the identification of high risk individuals during the Lung Health Check pilot to determine the risk of lung cancer and stratifying for LDCT screens. Improved patient selection has been identified as a priority to improve the sensitivity and specificity of lung health checks.

   B) Indeterminate Findings: In addition management of indeterminate 'nodules' which can be either small, possibly early cancers, or benign scarring requires delayed e.g. 3 or 12 month surveillance scans to stratify more invasive procedures such as lung biopsy to confirm the diagnosis. Blood biomarkers capable of identifying patients at increased risk of developing or harbouring lung cancer would be valuable adjuncts to protocols for surveillance and invasive monitoring. Nodules are seen in approximately 10% of scans.

   Existing clinical scores (e.g. Brock score) could be improved upon (see British Thoracic Society guidelines) and there remains significant clinical uncertainty about best management in patients with indeterminate nodules.

   1.3 Circulating and sputum biomarkers in lung cancer early diagnosis Identification of blood-based biomarkers is an important priority of lung health check research. Integrating biomarker data along with nodule size and/or volume with other radiological indices may enable improved risk stratification of surveillance, identifying those at high risk of lung cancer and requiring more frequent following up, versus those at low risk and requiring less follow up.

   Current technology recognises the potential to detect tumour specific proteins, metabolites or cell free DNA are examples of biological material in the circulating blood of patients with lung cancer. Existing approaches under investigation include genomics, epigenomics, microbiomics, gene methylation and metabolomics. Some groups have also looked at circulating tumour cells and immune responses to identify patients with higher risk of cancer. There is also a growing interest in using other bodily fluids, such as sputum, for this purpose. These have not reached readiness for clinical studies thus far but in other tumour types, such as in bowel cancer equivalent tests such as the nationally commissioned stool biomarker ('FIT test) improve diagnostic yield of bowel cancer screening to stratify resources more cost-effectively.

   Existing approaches in lung cancer screening research suggests that further work will be needed to identify circulating DNA from the smallest lesions where sensitivity remains highly variable between studies (10-100%) depending upon the technique selected and the stage of disease. There is a continued need to explore the role of these approaches in lung cancer early diagnosis populations, which will likely require a multi-modality approach of several technologies, for example combining genomics imaging biomarkers with radiomics. Sputum sensitivity has been shown previously to be in excess of 50% in a number of settings
2. Rationale CT screening of lung cancer offers the opportunity to diagnose early stage lung cancers which is associated with better prognosis - indeterminate results delay diagnosis whilst interval imaging is awaited to assess risk of cancer. This study will allow the investigators to examine the potential of blood-based biomarkers to augment CT screening for lung cancer.

Poor patient uptake and logistical issues are perceived to be key challenges to CT screening that may preclude clinical utility of a blood/sputum biomarker. Assessing whether such biomarkers can contribute to clinical decision making could then be explored.

Technologies for choosing laboratory biomarkers for risk stratification is evolving rapidly. Currently there is interest in genomics and circulating tumour cells, but as the potential for epigenomics, metabolomics, proteomics and exosome analysis evolve, the investigators hope to have prepared a suitable biobank with which can be used to challenge the latest of these approaches to the aim of stratification. This may be derived from germline or tumour-based markers of risk or be derived from the interaction between the tumour cells, host and immune response.

3. Hypothesis

1. Blood and sputum samples can be collected in patients attending lung health checks as part of the Lung Health Check pilot in West London at fixed and mobile scanners and safely transported for processing and storage in preparation for biomarker development.
2. The biomarkers will help to identify cohorts of

   1. High-risk patients in whom CT surveillance should be conducted more readily/frequently and diagnostic procedures performed earlier.
   2. Low-risk patients who might need reduced surveillance intensity.

7. Methodology This study is designed to collect sputum and blood specimens for laboratory development of a biomarker that will guide stratification and personalisation of CT screening study interval. The investigators seek access to basic, link-anonymized clinical and imaging data which can be integrated with data obtained from the sputum/blood biomarkers - this will be linked by the study ID number.

These data are not expected to influence clinical decision-making. There are no routine clinical arrangements in place to account for research findings. If a result is identified for which there is concern, which could be significant for the patient's care, the principle investigator will seek advice from the patient's clinical team. This is discussed in the patient information sheet and consent form.

This is a collaborative research project across RM Partners, Royal Brompton \& Harefield Hospitals NHS Foundation Trust, Royal Marsden Hospital NHS Foundation Trust, and Imperial College London.

'Lung Health Check' Biomarker Study

Lung Health Check Biomarker Study

The exploratory endpoints are indicators of whether for a given proposed laboratory biomarker test the sputum and blood specimens are deemed of suitable volume/quality to be subjected to the given laboratory approach (e.g. in the case of genomic analysis, this could be quantified as sample volume and DNA content RIN (RNA integrity number) as will be dictated by the laboratory protocol

The exploratory endpoints are indicators of whether for a given proposed laboratory biomarker test A given biomarker panel on sputum and/or peripheral blood samples and/or histopathological analysis of routine specimens (±combined clinical or imaging data) taken at the time of baseline LDCT screening scans differs between patients who receive a diagnosis of lung cancer after completion of follow-up imaging (or two years, whichever occurs sooner) and those whom do not.

The feasibility of the primary objective to collate a lung health check biobank will be reported as a percentage after the final participant recruited has donated both a baseline sample and also their final specimen (or on the same date should they decline to do so). The primary end point of the project will be considered feasible if consent to a blood test, collection and storage can be achieved in at least 50% of the 1000 patients approached for the biomarker study who undertake an LDCT scan.

The first secondary end point will be met if, a lung cancer genomics panel on sputum/peripheral blood samples taken at the time of the baseline LDCT screening scans differs between participants who receive a diagnosis of lung cancer at the time of the baseline scan (or associated biopsy) and those whom do not.

An additional secondary end point will be met if a lung cancer genomics panel on sputum or peripheral blood samples taken at baseline LDCT screening scans differs between patients who receive a diagnosis of lung cancer after completion of follow-up imaging (or two years, whichever occurs sooner) and those whom do not.

An additional secondary endpoint will be met if peripheral blood telomere length differs between those with interstitial lung abnormality and without and can predict those at higher risk of developing overt pulmonary fibrosis

Royal Brompton & Harefield NHS Foundation Trust

Imperial College London

Royal Marsden Partners Cancer Alliance

Royal Marsden NHS Foundation Trust

Digestive System Diseases

Gland and Hormone Related Diseases

Pancreatic Neoplasms

Pancreatic Cancer

Blood specimens will be obtained for the model-assigned high risk cohort at each collaborating HCO, over two years of recruitment period. Data of each participant will be electronically followed for observation of outcome measures for up to 3 years.

Blood samples will be collected from study participants at one time-point in the study, for the following:

1. tumor markers CEA and CA 19-9: 2 ml blood will be collected.
2. glycomics: 0.5 cc blood will be collected
3. ctDNA: 20 cc blood will be collected

Limor Appelbaum, MD

The purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records. Investigators would also like to test whether adding specific blood tests, can further help identify people who have a higher risk of pancreatic cancer than the general population, and would benefit from imaging in order to detect cancer early.

This research aims to identify people who have a higher risk of pancreatic cancer than the general population, by testing a double-screening strategy for pancreatic cancer. The purpose is to allow early detection of cancer, which potentially leads to cure.

The double-screening will include a computer-based model developed using clinical data from medical records, and three different blood tests for early detection of pancreatic cancer.

Participation in this study involves having medical records followed up for up to three years, and a single donation of blood specimens.

- This is a Combined Retrospective and Prospective Review:

* The first part of the study, involves collection of retrospective data from Electronic Health Record database (for the 3 collaborating HCOs) in order to deploy our EHR model, so that a high-risk group for pancreatic cancer can be identified. All individuals stratified into low, intermediate or high risk groups by the model, will be prospectively, electronically followed to assess outcome.
* The second stage is prospective, and involves requesting biological specimen donations from participants identified as high-risk, for biomarker testing. The prospective "observation period" is up to 3 years (depending on each subject's index date at retrospective recruitment and outcome). Biological specimens will be collected during the prospective "observation period,"

Specimen collection:

1. Tumor markers CEA, CA 19-9: 2 ml blood for will be collected in a serum separator tube, processed at each institution and serum stored locally in -80C freezers. Samples will be shipped in batches every 2 months to BIDMC for tumor marker analysis, and results recorded and blinded until the end of the study collection period.
2. Serum glycomics: 0.5 cc of blood will be collected in sterile Vacutainer tubes. Serum will be separated and aliquoted in 50 microliters aliquots, and frozen at -80C, for up to 3 years.
3. ctDNA, 20 cc of blood will be collected from patients in specialized tubes to stabilize the leukocytes and avoid contamination by genomic DNA. Samples will be processed within 48 hours to separate plasma, which will be frozen for batch analysis.

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

Prospective Multicenter Observational Study for Validation of a Pancreatic Cancer Risk Model and Assessment of the Predictive Value of Blood Biomarkers in a High-risk Cohort

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

The diagnosis of PDAC will be determined by ICD code (ICD10 codes C25.X, excluding C25.4), tumor registry records or pathology reports

stage at diagnosis per tumor registry/pathology report

National Institutes of Health (NIH)

Dana-Farber Cancer Institute

Beth Israel Deaconess Medical Center

Principal Investigator

Neoplasm Metastasis

Neoplastic Cells, Circulating

Neoplastic Processes

All Drugs and Chemicals

Mitogens

Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).

In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.

lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)

Surgery

Surgery on Demand

Florian Fitzal, MD

Michael Gnant, MD

Guenther Steger, MD

Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy

This study is a prospective, randomized, multicentre, study concerning the influence of local treatment on the patients with synchronous metastasized breast cancer. Patients will be stratified at inclusion according to the centre, the menopausal status (pre-menopausal, post-menopausal), the hormone-receptor status (ER-/PR-/not determinable; any PR and/or Er+), the HER-2 status (positive vs. negative/not determinable), the grading (G1/G2/not determinable vs. G3), location of metastases (visceral ± vs bone only), organs with metastases (single organ vs multiple organs) and use of first line chemotherapy (anthracycline ± vs. taxane vs others). Thereafter patients will be randomly assigned to receive either local therapy of the breast (lumpectomy or mastectomy + axillary surgery /± radiotherapy) versus no local therapy. Systemic therapy will be administered at the centers policy.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)	NCT05964504	Metastatic Brea... Lobular Breast ...	Blood Specimen	18 Years -	University of California, San Francisco
Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies	NCT00503893	Wilms' Tumor Aniridia	Questionnaire Blood specimen	-	M.D. Anderson Cancer Center
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)	NCT05964504	Metastatic Brea... Lobular Breast ...	Blood Specimen	18 Years -	University of California, San Francisco
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients	NCT01970930	Polycythemia Ve... Essential Throm...	Blood specimen	-	Icahn School of Medicine at Mount Sinai
'Lung Health Check' Biomarker Study	NCT04957433	Lung Cancer Cancer	Blood Specimen	55 Years - 75 Years	Royal Marsden NHS Foundation Trust
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort	NCT05287347	Pancreatic Aden...	Blood Specimen	50 Years - 100 Years	Beth Israel Deaconess Medical Center
'Lung Health Check' Biomarker Study	NCT04957433	Lung Cancer Cancer	Blood Specimen	55 Years - 75 Years	Royal Marsden NHS Foundation Trust
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)	NCT05964504	Metastatic Brea... Lobular Breast ...	Blood Specimen	18 Years -	University of California, San Francisco
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer	NCT01015625	Synchronous Met... Circulating Tum...	Surgery Surgery on Dema...	18 Years -	Austrian Breast & Colorectal Cancer Study Group
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer	NCT01015625	Synchronous Met... Circulating Tum...	Surgery Surgery on Dema...	18 Years -	Austrian Breast & Colorectal Cancer Study Group

Spots Global Cancer Trial Database for blood specimen